(E)-ethyl 3-(4-((3,5,6-trimethylpyrazin-2-yl)methoxy)phenyl)acrylate | 1018438-92-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-ethyl 3-(4-((3,5,6-trimethylpyrazin-2-yl)methoxy)phenyl)acrylate
• 英文别名: (E)-3-(4-((3, 5, 6-Trimethylpyrazin-2-yl) methoxy)-phenyl) acrylic acid ethyl ester；(e)-3-(4-((3,5,6-Trimethylpyrazin-2-yl)methoxy)-phenyl)acrylic acid ethyl ester；ethyl (E)-3-[4-[(3,5,6-trimethylpyrazin-2-yl)methoxy]phenyl]prop-2-enoate
• CAS: 1018438-92-0
• 化学式: C₁₉H₂₂N₂O₃
• 分子量: 326.395
• InChiKey: QYCIMTNIDKLHSQ-DHZHZOJOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  61.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (E)-ethyl 3-(4-((3,5,6-trimethylpyrazin-2-yl)methoxy)phenyl)acrylate 在 水 、 sodium hydroxide 、 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 4.0h， 以93%的产率得到(E)-3-(4-((3,5,6-trimethylpyrazin-2-yl)methoxy)phenyl)acrylic acid
  参考文献：
  名称：

  LIGUSTRAZINE AROMATIC ACID ETHER DERIVATIVE, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION

  摘要：

  公开号：

  EP2213666B1
• 作为产物：
  描述：

  4-香豆酸 在 氯化亚砜 、 四丁基溴化铵 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 30.0h， 生成 (E)-ethyl 3-(4-((3,5,6-trimethylpyrazin-2-yl)methoxy)phenyl)acrylate
  参考文献：
  名称：

  Ligustrazine derivatives. Part 5: Design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents

  摘要：

  A series of novel ligustrazinyloxy-cinnamic acid derivatives were designed, synthesized and evaluated for their inhibitory effect on adenosine diphosphate (ADP)-induced platelet aggregation in vitro, and also assayed for their protective effect against hydrogen peroxide (H2O2)-induced oxidative damage on ECV-304 cells. Some compounds exhibited high activity in one or both of the assays, of which, compound 2e displayed the highest protective effect on the proliferation of the damaged ECV-304 cells (EC50=0.020 mM), and compound 2f was the most active anti-platelet aggregation agent (EC50=0.054 mM). Structure activity relationships were briefly discussed. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.09.030

文献信息

• Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application
  申请人：Li Jiaming

  公开号：US20100228029A1

  公开（公告）日：2010-09-09

  Ligustrazine aromatic acid ether derivative of general formula I, its preparation method, pharmaceutical composition and application, wherein Ar is selected from aryl substituted aryl and substituted styryl, R is selected from hydrogen and alkyl with no more than 6 carbon atoms.

  利血平芳香酸醚衍生物I的通式，其制备方法，药物组成和应用，其中Ar选自芳基取代芳基和取代苯乙烯基，R选自氢和不超过6个碳原子的烷基。
• 4-((3, 5, 6-trimethylpyrazine-2-yl) methoxyl) benzoic acid and its derivatives
  申请人：——

  公开号：US08350033B2

  公开（公告）日：2013-01-08

  Ligustrazine aromatic acid ether derivative of general formula I, its preparation method, pharmaceutical composition and application, wherein Ar is selected from aryl substituted aryl and substituted styryl, R is selected from hydrogen and alkyl with no more than 6 carbon atoms.

  Ligustrazine芳香酸醚衍生物的一般式I，其制备方法，药物组合物和应用，其中Ar选自取代芳基和取代苯乙烯基，R选自氢和不超过6个碳原子的烷基。
• LIGUSTRAZINE AROMATIC ACID ETHER DERIVATIVE, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION
  申请人：Li, Jiaming

  公开号：EP2213666B1

  公开（公告）日：2012-02-15
• US8350033B2
  申请人：——

  公开号：US8350033B2

  公开（公告）日：2013-01-08
• Ligustrazine derivatives. Part 5: Design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents
  作者：Hongfei Chen、Guoning Li、Peng Zhan、Xinyong Liu

  DOI：10.1016/j.ejmech.2011.09.030

  日期：2011.11

  A series of novel ligustrazinyloxy-cinnamic acid derivatives were designed, synthesized and evaluated for their inhibitory effect on adenosine diphosphate (ADP)-induced platelet aggregation in vitro, and also assayed for their protective effect against hydrogen peroxide (H2O2)-induced oxidative damage on ECV-304 cells. Some compounds exhibited high activity in one or both of the assays, of which, compound 2e displayed the highest protective effect on the proliferation of the damaged ECV-304 cells (EC50=0.020 mM), and compound 2f was the most active anti-platelet aggregation agent (EC50=0.054 mM). Structure activity relationships were briefly discussed. (C) 2011 Elsevier Masson SAS. All rights reserved.